A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer.
about
Recent translational research: antiangiogenic therapy for breast cancer - where do we stand?Antiangiogenic mechanisms and factors in breast cancer treatmentTumor stroma as targets for cancer therapyThe role of integrins in TGFβ activation in the tumour stromaAntibodies as therapeutic agents: vive la renaissance!A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer.Integrin alpha(v)beta(3)-Targeted Cancer Therapy.Multiplexed protein profiling after aneurysmal subarachnoid hemorrhage: characterization of differential expression patterns in cerebral vasospasm.Mechanisms of tumour invasion and metastasis: emerging targets for therapy.Integrin targeted therapeutics.Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target?The alpha v integrin antagonists as novel anticancer agents: an update.Angiogenesis, lymphangiogenesis, and melanoma metastasis.Integrins: roles in cancer development and as treatment targets.Integrin inhibitors as a therapeutic agent for ovarian cancerPositron emission tomographic imaging of angiogenesis and vascular function.Progress report on the potential of angiogenesis inhibitors for neuro-oncology.Inhibition of angiogenesis in cancer patients.Angiogenesis and hematological malignancies.Targeting the stromal fibroblasts: a novel approach to melanoma therapy.Fibronectin as target for tumor therapy.The alphaVbeta6 integrin as a novel molecular target for colorectal cancer.Dual blockade of EGFR and ERK1/2 phosphorylation potentiates growth inhibition of breast cancer cells.Angiogenesis in melanoma.Minute dosages of alpha(nu)beta3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbitsIntegrins: signaling, disease, and therapy.Alpha-v integrins as therapeutic targets in oncology.Small molecular peptide-ScFv αvβ3 conjugates specifically inhibit lung cancer cell growth in vitro and in vivo.Specific targeting of human integrin α(v)β (3) with (111)In-labeled Abegrin™ in nude mouse models.Integrin targeted drug and gene delivery.Tumor angiogenesis: insights and innovations.Selecting Potential Targetable Biomarkers for Imaging Purposes in Colorectal Cancer Using TArget Selection Criteria (TASC): A Novel Target Identification Tool.Emerging molecular targets in melanoma invasion and metastasis.The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets.Platelet-targeted pharmacologic treatments as anti-cancer therapy.Differential regulation of monocyte cytokine release by αV and β(2) integrins that bind CD23.Cilengitide restrains the osteoclast-like bone resorbing activity of myeloma plasma cells.The minimum element of a synthetic peptide required to block prostate tumor cell migration.The Therapeutic Antibody LM609 Selectively Inhibits Ligand Binding to Human αVβ3 Integrin via Steric Hindrance.In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature.
P2860
Q24794969-2AC0A882-944A-4B3B-B89B-695CE3128905Q26751226-E1173EE5-156E-4D2E-AC38-09562E9F7738Q27015980-68807090-992F-43E1-A9C6-C3BA91C892DCQ28068373-8127B4CD-7E4D-4EDC-ACE5-AC3EE3ED071CQ33193524-E0586464-557D-44BB-B0E9-6C73E1119882Q33265964-772439B1-213E-46EE-85D1-44E6F3E778A8Q33983773-E19F42D2-22E6-4B7D-AA99-6B3358844D01Q34602988-7A2FDB7C-9C86-4F38-A8D1-E417D6951766Q34837655-08D4C1C5-5397-424E-9FCB-3CB1F5A467B6Q34912684-85FD6865-1210-4E7B-AE7C-9378A2BEAE90Q34966050-BDF1D110-C76B-47C6-B161-DCD87BF77431Q35011900-975422CF-E925-427A-8D94-D7485B98C87FQ35146591-648E974E-D405-4AF2-8E9A-841B94313CB9Q35647842-26E10FA8-ACBF-4FE2-8D66-48F93D50D596Q35660004-FCB95A36-8181-41D4-AD37-52DA52B267F9Q35905002-129E3966-6400-4867-A0A5-9216AF11ECC0Q35964419-56356E9D-2574-49FF-B496-8E6149167CC8Q36150646-6157C64E-3EEF-4CDB-BA28-F7670041BB66Q36194525-A43586DA-B85C-4E1B-9B92-46C69C859BBFQ36334912-F20D99CF-B748-4FA1-9CF4-A4D55DE17A72Q36354769-B8CDBC11-FED0-4B51-A208-AD9C365D825CQ36429644-90DD29DB-E5B8-4397-B375-22C23A86BD27Q36626059-92FF4A63-6BCE-4D94-B6E2-D7AAAB9A0DCAQ36626892-1A2882B9-B7BD-404C-AFB7-6153AEA0946CQ36804990-43FC4F1D-E10F-4CAD-BBCC-A66F7621C070Q36939598-41B4ABEA-0967-475D-9C50-2B9710F01794Q37008623-03D97B66-87F4-4B8F-8724-D6BFC99BB603Q37545105-A63FECC1-F3C2-421B-A782-40D7BE5DF1D4Q37592073-7E47DA58-AABF-4708-B84B-54EA6DE10619Q37679945-4A236D4D-1C9E-4C45-B03A-76A6BCBCDD6FQ37743207-3A092BC6-B020-4859-8B59-7C4352E9F9E0Q37860943-99CC33B9-256C-4946-99E0-7DBEF2AFB40EQ38055272-2D1A941D-E202-42FA-90BB-960B307AEF13Q38252537-763C61C0-8664-4CEA-B84E-4B703301FA81Q38657846-53B87622-3017-4867-B4B0-3DAFCC5A0071Q39393866-D4AAB960-6C95-47CC-AA98-FDCBF99AD336Q40147550-C4C5D224-6B58-4C60-9879-3C58BDDB1522Q40208879-1FCD90CD-AA19-472C-802B-6CDAFBC95C58Q46255773-7BF50FCF-C773-47F6-ABA3-9AB827F957CBQ46396196-80F44EF3-8E05-40E4-9F23-364B84F77109
P2860
A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
A pilot trial of Vitaxin, a hu ...... tients with metastatic cancer.
@en
type
label
A pilot trial of Vitaxin, a hu ...... tients with metastatic cancer.
@en
prefLabel
A pilot trial of Vitaxin, a hu ...... tients with metastatic cancer.
@en
P2093
P1476
A pilot trial of Vitaxin, a hu ...... tients with metastatic cancer.
@en
P2093
DelGrosso A
Khazaeli MB
LoBuglio AF
P304
P356
10.1089/108497801300189218
P577
2001-04-01T00:00:00Z